News & Resources

2017 Press Releases

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Media Contact:
Erika Hackmann
Y&R PR
Phone: 212-303-2305
Email:Erika.Hackmann@yr.com

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
08/08/17Orexigen Therapeutics Announces Second Quarter 2017 Financial ResultsPrinter Friendly Version
08/07/17Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and AustriaPrinter Friendly Version
07/26/17Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to EgyptPrinter Friendly Version
07/25/17Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017Printer Friendly Version
07/10/17Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug AddictionPrinter Friendly Version
05/16/17Orexigen Announces Activities at European Congress on Obesity 2017Printer Friendly Version
05/09/17Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017Printer Friendly Version
05/02/17Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcare ConferencePrinter Friendly Version
05/02/17Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic CountriesPrinter Friendly Version
04/25/17Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on May 9, 2017Printer Friendly Version
04/25/17Orexigen Therapeutics Announces New Drug Submission for Contrave© in CanadaPrinter Friendly Version
03/28/17Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016Printer Friendly Version
03/27/17Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in ItalyPrinter Friendly Version
03/07/17Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017Printer Friendly Version
02/07/17Orexigen Therapeutics to Speak at Upcoming Investor ConferencesPrinter Friendly Version
01/25/17Orexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmacéuticos Rovi, S.A.Printer Friendly Version
01/06/17Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl extended-release tablets) Real-World Study Results in "Obesity"Printer Friendly Version
01/05/17Orexigen Therapeutics Highlights Key Business Priorities for 2017Printer Friendly Version
01/03/17Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient Focused Campaign to Educate Consumers on the Role of the Brain in Weight LossPrinter Friendly Version